Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, is the manufacturer of Zytiga [1].
Who else makes Zytiga?
While Janssen Biotech is the primary manufacturer, other companies may be involved in the supply chain or distribution of Zytiga. However, Janssen holds the marketing authorization in many regions.
What is Zytiga used for?
Zytiga (abiraterone acetate) is a prescription medication used to treat certain types of prostate cancer [1]. It is specifically indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy [1]. It may also be used in combination with prednisone for patients with mCRPC who have not received prior chemotherapy [1].
When does Zytiga patent expire?
The patent landscape for Zytiga is complex, with multiple patents covering the drug and its uses. As of recent information, some key patents related to abiraterone acetate have expired or are nearing expiry, opening the door for generic competition. For detailed and up-to-date patent expiry information, DrugPatentWatch.com is a valuable resource [2].
Can generic versions of Zytiga be made?
Yes, following the expiry of relevant patents, generic versions of abiraterone acetate can be manufactured and marketed. This process allows for the availability of lower-cost alternatives to the branded drug.
How does Zytiga work?
Zytiga works by inhibiting an enzyme called CYP17A1, which is involved in the production of androgens, including testosterone [1]. In prostate cancer, the growth of cancer cells can be dependent on androgens. By blocking the production of these hormones, Zytiga helps to slow or stop the growth of prostate cancer [1]. It is often used in combination with prednisone, a corticosteroid, to manage side effects and further reduce androgen levels [1].
What are the risks or side effects of Zytiga?
Common side effects of Zytiga include fatigue, joint pain, hot flashes, nausea, diarrhea, and high blood pressure [1]. More serious side effects can include liver problems, heart problems, and adrenal insufficiency [1]. Patients should discuss any concerns with their healthcare provider.
How does Zytiga compare to other prostate cancer treatments?
Zytiga is a targeted therapy that works differently from traditional chemotherapy. It is often used in advanced prostate cancer stages. Its effectiveness and side effect profile are compared against other treatments like docetaxel, enzalutamide, and apalutamide in clinical studies and practice guidelines.
Who is the competition for Zytiga?
The primary competition for Zytiga comes from other drugs used to treat castration-resistant prostate cancer, including enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa). Generic versions of abiraterone acetate also represent significant competition.
Where can I find more information on Zytiga patents?
Detailed information on Zytiga patents, including expiry dates and any ongoing litigation, can be found on specialized resources like DrugPatentWatch.com [2].
What is the cost of Zytiga?
The cost of Zytiga can vary significantly depending on insurance coverage, pharmacy, and whether it is the branded product or a generic version. Branded Zytiga is typically an expensive medication, but generic abiraterone acetate is generally more affordable.
Sources:
1. Janssen Biotech, Inc. Data Sheet for Zytiga.
2. DrugPatentWatch.com